<p>Twist Bioscience Corporation reported revenues of USD 103.70 million for the three months ended December 31, 2025, representing an increase of 17 percent. Gross margin improved to 52.0 percent for the period, up from 48.3 percent, primarily due to increased revenues and ongoing cost-saving initiatives. Loss from operations decreased to USD 32.90 million, driven by higher revenues and gross profit, as well as a decrease in research and development expenses, despite an increase in selling, general and administrative expenses. Net cash used in operating activities rose to USD 24.80 million. By industry, revenues for the period were distributed as follows: therapeutics USD 37.23 million, diagnostics USD 35.32 million, industry and applied USD 6.12 million, academic research and government USD 12.22 million, and global supply partners USD 12.82 million. The revenue growth was primarily attributed to the NGS Applications and DNA Synthesis and Protein Solutions segments. The company noted continued efforts in commercializing additional products in synthetic biology and biologic drug sectors, alongside leveraging its manufacturing facility in Wilsonville, Oregon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000019), on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

IBBQ

TWST

<p>Twist Bioscience Corporation reported a 16.9% increase in Q4 revenues, reaching USD 103.7 million for the period ending December 31, 2025. Gross margin improved to 52.0%, up from 48.3%. The loss from operations decreased to USD 32.9 million, aided by higher revenues and reduced R&D expenses. Revenue distribution included therapeutics at USD 37.23 million and diagnostics at USD 35.32 million. Growth was driven by NGS Applications and DNA Synthesis segments, with ongoing efforts in synthetic biology and biologic drug commercialization.</p>

Twist Bioscience Q4 revenues rise 16.9% to USD 103.7 million